Journal of Clinical Endocrinology & Metabolism, Vol 80, 529-533, Copyright © 1995 by Endocrine Society

ARTICLES

Endogenous inhibitors of 11 beta-hydroxysteroid dehydrogenase in hypertension

BR Walker, I Aggarwal, PM Stewart, PL Padfield and CR Edwards
Department of Medicine, University of Edinburgh, Western General Hospital, Scotland.

Exogenous inhibitors of 11 beta-hydroxysteroid dehydrogenase (e.g. glycyrrhetinic acid, a constituent of licorice) raise blood pressure by allowing cortisol to activate mineralocorticoid receptors. Endogenous 11 beta-dehydrogenase inhibitors called glycyrrhetinic acid-like factors (GALFs), have been extracted from urine. Increased GALFs could explain the impairment of 11 beta-dehydrogenase in essential hypertension and ectopic ACTH syndrome. We extracted urine on Sep-Paks and quantified GALFs by their inhibition of 11 beta-dehydrogenase bioactivity in microsomes from rat liver. GALFs have no diurnal rhythm and were no different after dexamethasone treatment, in patients with low ACTH, on in 4 patients with ectopic ACTH secretion. In 79 subjects, GALF excretion did not correlate with blood pressure. In 17 subjects, GALF excretion did not correlate with indices of mineralocorticoid receptor activation on 11 beta-dehydrogenase activity. We conclude that GALFs are not ACTH dependent and have no measurable effect on 11 beta- dehydrogenase in vivo. In hypertension associated with impaired 11 beta- dehydrogenase activity GALFs are unlikely to play a pathophysiological role.

This article has been cited by other articles:

				A. E. Michael and A. T. Papageorghiou Potential significance of physiological and pharmacological glucocorticoids in early pregnancy Hum. Reprod. Update, September 1, 2008; 14(5): 497 - 517. [Abstract] [Full Text] [PDF]

				M. Quinkler and P. M. Stewart Hypertension and the Cortisol-Cortisone Shuttle J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2384 - 2392. [Abstract] [Full Text] [PDF]

				J. A. Whitworth, G. J. Mangos, and J. J. Kelly Cushing, Cortisol, and Cardiovascular Disease Hypertension, November 1, 2000; 36(5): 912 - 916. [Abstract] [Full Text] [PDF]

				Y. Takeda, S. Inaba, K. Furukawa, and I. Miyamori Renal 11ß-Hydroxysteroid Dehydrogenase in Genetically Salt-Sensitive Hypertensive Rats Hypertension, December 1, 1998; 32(6): 1077 - 1082. [Abstract] [Full Text] [PDF]

				G. Mazzocchi, G. P. Rossi, G. Neri, L. K. Malendowicz, G. Albertin, and G. G. Nussdorfer 11ß-Hydroxysteroid dehydrogenase expression and activity in the human adrenal cortex FASEB J, November 1, 1998; 12(14): 1533 - 1539. [Abstract] [Full Text]

				P. C. White, T. Mune, and A. K. Agarwal 11{beta}-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess Endocr. Rev., February 1, 1997; 18(1): 135 - 156. [Abstract] [Full Text]

				Y. Takeda, I. Miyamori, K. Iki, S. Inaba, K. Furukawa, H. Hatakeyama, T. Yoneda, and R. Takeda Endogenous Renal 11ß-Hydroxysteroid Dehydrogenase Inhibitory Factors in Patients With Low-Renin Essential Hypertension Hypertension, February 1, 1996; 27(2): 197 - 201. [Abstract] [Full Text]

				B. R. Walker, P. M. Williamson, M. A. Brown, J. W. Honour, C. R. W. Edwards, and J. A. Whitworth 11ß-Hydroxysteroid Dehydrogenase and Its Inhibitors in Hypertensive Pregnancy Hypertension, April 1, 1995; 25(4): 626 - 630. [Abstract] [Full Text]